Cargando…

Assessment of perfusion deficit with early phases of [(18)F]PI-2620 tau-PET versus [(18)F]flutemetamol-amyloid-PET recordings

PURPOSE: Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed that the early, perfusion-weighted phases of amyloid- or tau-PET recordings serve to detect cerebrometabolic deficits equally...

Descripción completa

Detalles Bibliográficos
Autores principales:	Völter, Friederike, Beyer, Leonie, Eckenweber, Florian, Scheifele, Maximilian, Bui, Ngoc, Patt, Marianne, Barthel, Henryk, Katzdobler, Sabrina, Palleis, Carla, Franzmeier, Nicolai, Levin, Johannes, Perneczky, Robert, Rauchmann, Boris-Stephan, Sabri, Osama, Hong, Jimin, Cumming, Paul, Rominger, Axel, Shi, Kuangyu, Bartenstein, Peter, Brendel, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027797/ https://www.ncbi.nlm.nih.gov/pubmed/36572740 http://dx.doi.org/10.1007/s00259-022-06087-y

Ejemplares similares

Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [(18)F]-PI-2620 tau-PET signal
por: Schönecker, Sonja, et al.
Publicado: (2023)

Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy
por: Song, Mengmeng, et al.
Publicado: (2021)

Additive value of [(18)F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
por: Katzdobler, Sabrina, et al.
Publicado: (2022)

Multicenter (18)F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
por: Rullmann, Michael, et al.
Publicado: (2022)

Binding characteristics of [(18)F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET
por: Song, Mengmeng, et al.
Publicado: (2021)

Early-phase [(18)F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
por: Beyer, Leonie, et al.
Publicado: (2020)

Assessment of (18)F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2020)

[(18)F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data
por: Ballweg, Anna, et al.
Publicado: (2023)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Early-phase (18)F-FP-CIT and (18)F-flutemetamol PET were significantly correlated
por: An, Young-Sil, et al.
Publicado: (2021)

Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases
por: Daerr, Sonja, et al.
Publicado: (2016)

Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [(18)F]PI-2620
por: Willroider, Marie, et al.
Publicado: (2021)

Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies
por: Heeman, Fiona, et al.
Publicado: (2019)

Amyloid-Targeting PET Tracer [(18)F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Hellberg, Sanna, et al.
Publicado: (2019)

Appropriate reference region selection of (18)F-florbetaben and (18)F-flutemetamol beta-amyloid PET expressed in Centiloid
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Clinical significance of focal ß-amyloid deposition measured by (18)F-flutemetamol PET
por: Kim, Si Eun, et al.
Publicado: (2020)

Impact of Partial Volume Correction on [(18)F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome
por: Schuster, Sebastian, et al.
Publicado: (2022)

A Case of Early Onset Alzheimer's Disease Diagnosed by (18)F Flutemetamol PET Image
por: Kim, Jeong-Hoon, et al.
Publicado: (2018)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Is Amyloid Burden Measured by (18)F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
por: Müller, Ebba Gløersen, et al.
Publicado: (2022)

Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Comparison of (18)F-T807 and (18)F-THK5117 PET in a Mouse Model of Tau Pathology
por: Brendel, Matthias, et al.
Publicado: (2018)

Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration
por: Brendel, Matthias, et al.
Publicado: (2017)

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
por: Ikonomovic, Milos D., et al.
Publicado: (2016)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben
por: Son, Hye Joo, et al.
Publicado: (2018)

Author Correction: Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2021)

Dual-Phase β-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome
por: Schmitt, Julia, et al.
Publicado: (2021)

Cross-Sectional Comparison of Small Animal [(18)F]-Florbetaben Amyloid-PET between Transgenic AD Mouse Models
por: Brendel, Matthias, et al.
Publicado: (2015)

Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
por: Thal, Dietmar Rudolf, et al.
Publicado: (2018)

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Pemberton, Hugh G., et al.
Publicado: (2023)

[(18)F]MPPF and [(18)F]FDG μPET imaging in rats: impact of transport and restraint stress
por: Buchecker, Verena, et al.
Publicado: (2020)

Image reconstruction methods affect software-aided assessment of pathologies of [(18)F]flutemetamol and [(18)F]FDG brain-PET examinations in patients with neurodegenerative diseases
por: Lindström, Elin, et al.
Publicado: (2020)

Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [(18)F]-FDG PET/CT
por: Alberts, Ian, et al.
Publicado: (2021)

Infrequent false positive [(18)F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
por: Ikonomovic, Milos D., et al.
Publicado: (2018)

Validation of an electronic image reader training programme for interpretation of [(18)F]flutemetamol β-amyloid PET brain images
por: Buckley, Christopher J., et al.
Publicado: (2017)

Initial Physician Experience with [(18)F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan
por: Hattori, Naoya, et al.
Publicado: (2020)

Quantitative Evaluation of (18)F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
por: Matsuda, Hiroshi, et al.
Publicado: (2021)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6sgtskl6orfv4gnk68hlcbsft1